Exploring the binding conformations of bulkier dipeptide amide inhibitors in constitutive nitric oxide synthases

被引:13
作者
Li, HY
Flinspach, ML
Igarashi, J
Jamal, J
Yang, WP
Gómez-Vidal, JA
Litzinger, EA
Huang, H
Erdal, EP
Silverman, RB
Poulos, TL [1 ]
机构
[1] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA
[2] Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA
[3] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA
[4] Univ Calif Irvine, Ctr Chem & Struct Biol, Irvine, CA 92697 USA
[5] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA
[6] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA
[7] Northwestern Univ, Ctr Drug Discovery & Chem Biol, Evanston, IL 60208 USA
关键词
D O I
10.1021/bi0513610
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series Of L-nitroarginine-based dipeptide inhibitors are highly selective for neuronal nitric oxide synthase (nNOS) over the endothelial isoform (eNOS). Crystal structures of these dipeptides bound to both isoforms revealed two different conformations, curled in nNOS and extended in eNOS, corresponding to higher and lower binding, affinity to the two isoforms, respectively. In previous studies we found that the primary reason for selectivity is that Asp597 in nNOS, which is Asn368 in eNOS, provides greater electrostatic stabilization in the inhibitor complex. While this is the case for smaller dipeptide inhibitors, electrostatic stabilization may no longer be the sole determinant for isoform selectivity with bulkier dipeptide inhibitors. Another residue farther away from the active site, Met336 in nNOS (Val106 in eNOS), is in contact with bulkier dipeptide inhibitors. Double mutants were made to exchange the D597/M336 pair in nNOS with N368/V106 in eNOS. Here we report crystal structures and inhibition constants for bulkier dipeptide inhibitors bound to nNOS and eNOS that illustrate the important role played by residues near the entry to the active site in isoform selective inhibition.
引用
收藏
页码:15222 / 15229
页数:8
相关论文
共 32 条
[11]   NITRIC OXIDES SYNTHASES - PROPERTIES AND CATALYTIC MECHANISM [J].
GRIFFITH, OW ;
STUEHR, DJ .
ANNUAL REVIEW OF PHYSIOLOGY, 1995, 57 :707-736
[12]   Reduced amide bond peptidomimetics.: (4S)-N-(4-amino-5-[aminoalkyl]aminopentyl)-N′-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase [J].
Hah, JM ;
Roman, LJ ;
Martásek, P ;
Silverman, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (16) :2667-2670
[13]  
HEVEL JM, 1994, METHOD ENZYMOL, V233, P250
[14]   SITE-DIRECTED MUTAGENESIS BY OVERLAP EXTENSION USING THE POLYMERASE CHAIN-REACTION [J].
HO, SN ;
HUNT, HD ;
HORTON, RM ;
PULLEN, JK ;
PEASE, LR .
GENE, 1989, 77 (01) :51-59
[15]   Inhibition of nitric oxide synthase as a potential therapeutic target [J].
Hobbs, AJ ;
Higgs, A ;
Moncada, S .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :191-220
[16]   Nω-nitroarginine-containing dipeptide amides.: Potent and highly selective inhibitors of neuronal nitric oxide synthase [J].
Huang, H ;
Martasek, P ;
Roman, LJ ;
Masters, BSS ;
Silverman, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) :3147-3153
[17]   Synthesis and evaluation of peptidomimetics as selective inhibitors and active site probes of nitric oxide synthases [J].
Huang, H ;
Martásek, P ;
Roman, LJ ;
Silverman, RB .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2938-2945
[18]  
JONES AF, 1999, MODERN HYPERTENSION, V1, P10
[19]  
Kankuri E, 2001, J PHARMACOL EXP THER, V298, P1128
[20]   NITRIC-OXIDE - A NEW PARADIGM FOR 2ND-MESSENGERS [J].
KERWIN, JF ;
LANCASTER, JR ;
FELDMAN, PL .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (22) :4343-4362